MimiVax Announces Positive Interim Results from Phase II Trial of SurVaxM Immunotherapy for the Treatment of Newly Diagnosed Glioblastoma
May 21, 2018 08:00 ET | MimiVax LLC
Interim analysis shows significant survival benefit compared to historical standard of care;Combination of SurVaxM and standard therapy was well-tolerated, with few serious side effects;MimiVax to...
MimiVax to Present Interim Phase II Trial Data on Multi-focal Immunotherapy SurVaxM for the Treatment of Glioblastoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
May 15, 2018 08:00 ET | MimiVax LLC
BUFFALO, N.Y., May 15, 2018 (GLOBE NEWSWIRE) -- MimiVax LLC, a clinical-stage biotechnology company developing immunotherapeutics and targeted therapies for cancer treatment, today announced that...